Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Revenue (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Revenue for 6 consecutive years, with $875000.0 as the latest value for Q3 2025.

  • For Q3 2025, Revenue rose 351.03% year-over-year to $875000.0; the TTM value through Sep 2025 reached $2.9 million, up 1371.65%, while the annual FY2024 figure was $2.0 million, N/A changed from the prior year.
  • Revenue hit $875000.0 in Q3 2025 for Cyclerion Therapeutics, up from $93000.0 in the prior quarter.
  • Across five years, Revenue topped out at $3.0 million in Q2 2021 and bottomed at $62000.0 in Q1 2021.
  • Average Revenue over 4 years is $728090.9, with a median of $348000.0 recorded in 2021.
  • Year-over-year, Revenue tumbled 93.89% in 2021 and then skyrocketed 1046.77% in 2022.
  • Cyclerion Therapeutics' Revenue stood at $533000.0 in 2021, then plummeted by 42.59% to $306000.0 in 2022, then surged by 490.2% to $1.8 million in 2024, then crashed by 51.55% to $875000.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $875000.0, $93000.0, and $81000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.